We next tested if treatment with an ASO that targets MECP2 for RNase H1-mediated degradation (MECP2 ASO) in human neurons can normalize MeCP2-induced gene expression similar to what occurs in MDS mice treated with MECP2 ASO [13, 14]. This evidence concerns the gene MECP2 and myelodysplastic syndrome.